Metz R, Namer M, Adenis L, Audhuy B, Bugat R, Colombel P, Couette J E, Grise P, Khater R, LePorz B
Centre Alexis Vautrin, Nancy, France.
Am J Clin Oncol. 1988;11 Suppl 2:S112-4. doi: 10.1097/00000421-198801102-00027.
From April 1984 to May 1986, 129 patients with prostate cancer entered a prospective trial with a new LH-RH agonist, Zoladex. Mean age was 72 years (range of 45-94 years) and, in most cases, patients had metastatic disease, not previously treated by chemotherapy or hormone therapy. Patients received a monthly injection of 3.6 mg. Serum testosterone was lowered into the range of castrate levels after 4 weeks of treatment. In 105 evaluable patients at 3 months, a 65% partial response (PR) rate was observed, with 11% stable and 24% progressive disease. Median time to progression was 37 weeks. Analysis of objective criteria revealed 30% PR for prostate volume and 51% CR-PR for prostatic acid phosphatases. Seventeen percent of lytic metastases had recalcified. One hundred twenty-nine patients were evaluable for toxicity. Endocrinological side effects were common: decrease in libido, 92%; impotence, 86%; hot flushes, 48%; and breast swelling or tenderness, 9%. Nonendocrinologic side effects were rare. The treatment is generally well accepted by patients owing to the convenient depot formulation and to the minor side effects.
1984年4月至1986年5月，129例前列腺癌患者参与了一项使用新型促黄体生成激素释放激素（LH-RH）激动剂——诺雷德的前瞻性试验。患者平均年龄为72岁（45 - 94岁），大多数患者患有转移性疾病，此前未接受过化疗或激素治疗。患者每月注射3.6毫克。治疗4周后，血清睾酮水平降至去势水平范围。在3个月时可评估的105例患者中，观察到65%的部分缓解（PR）率，11%病情稳定，24%病情进展。中位疾病进展时间为37周。客观标准分析显示，前列腺体积的部分缓解率为30%，前列腺酸性磷酸酶的完全缓解 - 部分缓解率为51%。17%的溶骨性转移灶出现重新钙化。129例患者可评估毒性。内分泌副作用常见：性欲减退92%；阳痿86%；潮热48%；乳房肿胀或压痛9%。非内分泌副作用罕见。由于剂型方便且副作用较小，该治疗方法总体上为患者所接受。
